Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

IBRX stock hub

ImmunityBio, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

IBRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

8.9B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

IBRX

In the news

Latest news · IBRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-67

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All IBRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

207

Groups with data

Currency

USD

Showing 207 of 207 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001326110
Company name	ImmunityBio, Inc.
Country	United States
Country code	US
Cusip	45256X103
Employees	691
Employees Change	11%
Employees Change Percent	1.62
Enterprise value	$9.7B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US45256X1037
Last refreshed	2026-05-10
Market cap	$8.9B
Market cap category	Mid-Cap
Price	$8.51
Price currency	USD
Rev Per Employee	204,018.81x
Sector	Healthcare
Sic	2836
Symbol	IBRX
Website	https://immunitybio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-9.59%
EV Sales Forward	41.68x
EV/Sales	68.5x
FCF yield	-3.35%
P/S ratio	63.22x
PS Forward	38.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-185.41%
EBITDA Margin	-174.08%
Gross margin	99.34%
Gross Profit	$140M
Gross Profit Growth	349.38%
Gross Profit Growth Q	167.14%
Gross Profit Growth3 Y	520.57%
Gross Profit Growth5 Y	199.72%
Net Income	$-854.5M
Net Income Growth Years	2%
Pretax Margin	-606.12%
Profit Per Employee	$-1.2M
ROA	-34.38
Roa5y	-49.39
ROCE	-45.17
ROIC	-67.01

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	350.73%
Cagr3y	15.38%
Cagr5y	-12.66%
EPS Growth Years	2
Revenue Growth	351.53x
Revenue Growth Q	167.64x
Revenue Growth Quarters	8x
Revenue Growth Years	3x
Revenue Growth3 Y	521.94x
Revenue Growth5 Y	200.12x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.3
Assets	$646.6M
Cash	$380.9M
Current Assets	$453M
Current Liabilities	$68M
Debt	$1.1B
Equity	$-869.1M
Interest Coverage	-2.33
Liabilities	$1.5B
Long Term Assets	$193.7M
Long Term Liabilities	$1.4B
Net Cash	$-743.7M
Net Cash By Market Cap	$-8.34
Tangible Book Value	$-882.9M
Tangible Book Value Per Share	$-0.84
WACC	5.01

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.67
Inventory Turnover	0.21
Net Working Capital	$12.7M
Quick ratio	6.24
Working Capital	$385M
Working Capital Turnover	$0.63

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-29.76%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	350.27%
200-day SMA	4.43
3Y total return	53.61%
50-day SMA	7.94
50-day SMA vs 200-day SMA	50over200
5Y total return	-49.16%
All Time High	40.83
All Time High Change	-79.16%
All Time High Date	2021-03-11
All Time Low	1.21
All Time Low Change	603.31%
All Time Low Date	2023-03-15
ATR	0.65
Beta	0.07
Beta1y	2.52
Beta2y	1.93
Ch YTD	329.8
High	8.56
High52	12.43
High52 Date	2026-02-25
High52ch	-31.54%
Low	7.58
Low52	1.91
Low52 Date	2025-05-08
Low52ch	345.55%
Ma50ch	7.22%
Premarket Change Percent	1.16
Premarket Price	$7.85
Premarket Volume	211,115
Price vs 200-day SMA	92.1%
RSI	58.69
RSI Monthly	61.8
RSI Weekly	66.5
Sharpe ratio	1.87x
Sortino ratio	3.72
Total Return	-29.76%
Tr YTD	329.8
Tr1m	24.05%
Tr1w	19.69%
Tr3m	40.66%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	2
Analyst Price Target Top	$11
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.07
Earnings Revenue Estimate	43,369,000x
Earnings Revenue Estimate Growth	162.57x
Operating Income	$-261.4M
Operating margin	-185.4
Price target	$12.57
Price Target Change	$47.71
Price Target Change Top	$29.26

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	394,033,585%
Float Percent	37.62%
Net Borrowing	75,904,000
Shares Insiders	28.24%
Shares Institutions	17.43%
Shares Out	1,047,353,977
Shares Qo Q	3.76%
Shares Yo Y	29.76%
Short Float	35.61%
Short Ratio	6.18
Short Shares	13.4

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-334.3M
Average Volume	13,131,826.8x
Bv Per Share	-0.83
CAPEX	$-4.5M
Ch1m	24.05
Ch1w	19.69
Ch1y	350.3
Ch3m	40.66
Ch3y	53.61
Ch5y	-49.16
Ch6m	299.5
Change	9.66%
Change From Open	7.99
Close	7.76
Days Gap	1.55
Depreciation Amortization	15,976,000
Dollar Volume	137,894,048.7
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-261.4M
EBITDA	$-245.4M
EPS	$-0.89
F Score	3
FCF	$-298.9M
FCF EV Yield	-3.1x
FCF Per Share	$-0.29
Financing CF	625,149,000
Fiscal Year End	December
Founded	2,014
Goodwill	910,000
Income Tax	$108,000
Investing CF	-185,580,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-23
Ma150	5.07
Ma150ch	67.88%
Ma20	7.64
Ma20ch	11.45%
Net CF	145,326,000
Next Earnings Date	2026-08-04
Open	7.88
Optionable	Yes
Position In Range	94.9
Post Close	8.51
Postmarket Change Percent	-0.94
Postmarket Price	$8.43
Ppne	146,075,000
Pre Close	7.76
Price Date	2026-05-08
Relative Volume	1.23x
Revenue	140,977,000x
SBC By Revenue	25.14x
Share Based Comp	35,441,000
Tax By Revenue	0.08x
Tr6m	299.53%
Us State	California
Views	90
Volume	16,203,766
Z Score	-8.48

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does IBRX pay a dividend?

Capital-return profile for this ticker.

Performance

IBRX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns IBRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+17.4%

Float: +37.6% of shares outstanding

Insider ownership

+28.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

IBRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

58.7

Neutral momentum band

Price vs 200-day MA

+92.1%

50/200-day relationship not available

Beta (5Y)

0.07

Less volatile than the market

Sharpe ratio

1.87

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About IBRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current IBRX stock rating?

ImmunityBio, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full IBRX analysis?

The full report lives at /stocks/IBRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for IBRX?

The latest report frames IBRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the IBRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.